BioCentury
ARTICLE | Company News

EpiGenesis, Hybridon in respiratory deal

April 23, 2001 7:00 AM UTC

The companies will develop and market up to five antisense drugs for respiratory diseases. The collaboration combines HYBN's antisense chemistry with the RASON (respirable antisense oligonucleotide) t...